Publication on Dec. 12, 2024, of data analysis regarding Merck & Co. Inc.’s Winrevair (sotatercept) in Clinical Pharmacology & Therapeutics may have put investors in mind of the odds for the activin signaling inhibitor beyond pulmonary arterial hypertension, the indication for which Winrevair was approved by the U.S. FDA in March of last year.